Probing p53 biological functions through the use of genetically engineered mouse models

被引:57
作者
Attardi, LD
Donehower, LA
机构
[1] Stanford Univ, Sch Med, Dept Radiat Oncol & Genet, Stanford, CA 94305 USA
[2] Baylor Coll Med, Dept Mol Virol & Microbiol & Mol & Cellular Biol, Houston, TX 77030 USA
关键词
Tumor suppressor gene; p53; gene; genetically engineered mouse model;
D O I
10.1016/j.mrfmmm.2004.08.022
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The p53 tumor suppressor gene is rendered dysfunctional in the majority of human cancers. To model the effects of p53 dysfunction in an experimentally manipulable organismal context, genetically engineered inbred mice have been the models of choice. Transgenic and knock-out technologies have been utilized to generate an array of different p53 germ line alterations. As expected, many (though not all) of the mutant p53 mouse models are susceptible to enhanced spontaneous and carcinogen-induced tumors of a variety of types. A number of different variables affect the incidence and spectrum of tumors in p53 mutant mice. These include strain background, the nature of the p53 mutation, the presence of wild-type p53 (in addition to mutant p53), exposure to physical and chemical mutagens, or introduction of other cancer-associated genes into the mutant p53 background. In addition to their role in furthering our understanding of the mechanisms of cancer initiation and progression, these models have led to unexpected insights into p53 function in embryogenesis and aging. With the development of ever more sophisticated methods for manipulating the mouse genome, new p53 models are on the horizon, which should deliver advances that will provide not only important mechanistic insights but also discoveries of great clinical relevance. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:4 / 21
页数:18
相关论文
共 105 条
[11]   p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis [J].
Chin, L ;
Artandi, SE ;
Shen, Q ;
Tam, A ;
Lee, SL ;
Gottlieb, GJ ;
Greider, CW ;
DePinho, RA .
CELL, 1999, 97 (04) :527-538
[12]   p53 in embryonic development: maintaining a fine balance [J].
Choi, J ;
Donehower, LA .
CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 55 (01) :38-47
[13]   Mouse models of tumor development in neurofibromatosis type 1 [J].
Cichowski, K ;
Shih, TS ;
Schmitt, E ;
Santiago, S ;
Reilly, K ;
McLaughlin, ME ;
Bronson, RT ;
Jacks, T .
SCIENCE, 1999, 286 (5447) :2172-2176
[14]   Alternative models for Carcinogenicity testing: Weight of evidence evaluations across models [J].
Cohen, SM .
TOXICOLOGIC PATHOLOGY, 2001, 29 :183-190
[15]   WILD-TYPE P53 MEDIATES APOPTOSIS BY E1A, WHICH IS INHIBITED BY E1B [J].
DEBBAS, M ;
WHITE, E .
GENES & DEVELOPMENT, 1993, 7 (04) :546-554
[16]   DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation [J].
Difilippantonio, MJ ;
Zhu, J ;
Chen, HT ;
Meffre, E ;
Nussenzweig, MC ;
Max, EE ;
Ried, T ;
Nussenzweig, A .
NATURE, 2000, 404 (6777) :510-514
[17]   MICE DEFICIENT FOR P53 ARE DEVELOPMENTALLY NORMAL BUT SUSCEPTIBLE TO SPONTANEOUS TUMORS [J].
DONEHOWER, LA ;
HARVEY, M ;
SLAGLE, BL ;
MCARTHUR, MJ ;
MONTGOMERY, CA ;
BUTEL, JS ;
BRADLEY, A .
NATURE, 1992, 356 (6366) :215-221
[18]   Does p53 affect organismal aging? [J].
Donehower, LA .
JOURNAL OF CELLULAR PHYSIOLOGY, 2002, 192 (01) :23-33
[19]  
Donehower LA, 1997, CANCER SURV, V29, P329
[20]   The p53-deficient mouse: A model for basic and applied cancer studies [J].
Donehower, LA .
SEMINARS IN CANCER BIOLOGY, 1996, 7 (05) :269-278